Brindle & Bay Financial Advisors LLC Invests $778,000 in Merck & Co., Inc. $MRK

Brindle & Bay Financial Advisors LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 7,391 shares of the company’s stock, valued at approximately $778,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chemung Canal Trust Co. grew its holdings in Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after buying an additional 13,285 shares in the last quarter. First Pacific Financial grew its holdings in Merck & Co., Inc. by 14.7% during the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co grew its holdings in Merck & Co., Inc. by 9.6% during the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after buying an additional 18,187 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after buying an additional 32,114 shares in the last quarter. Finally, Coldstream Capital Management Inc. grew its holdings in Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after buying an additional 13,940 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This represents a 63.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the company’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the transaction, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. This represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is owned by company insiders.

Merck & Co., Inc. Stock Down 2.4%

Shares of NYSE:MRK opened at $111.83 on Friday. The company has a market capitalization of $276.21 billion, a PE ratio of 15.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The business has a fifty day moving average price of $118.61 and a two-hundred day moving average price of $106.88. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts forecast that Merck & Co., Inc. will post 4.92 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a multi‑year, enterprise‑wide partnership with Google Cloud to deploy Gemini AI and advanced cloud infrastructure for drug discovery, manufacturing and operations — a strategic move that could improve R&D productivity and long‑term margins. Read More. Read More.
• Positive Sentiment: Merck won FDA Priority Review for KEYTRUDA regimens in muscle‑invasive bladder cancer — a potential near‑term upsid e for oncology revenue if approved, supporting key growth drivers beyond vaccines. Read More.
• Positive Sentiment: Regulatory approval momentum: the company secured FDA approval for Idvynso (doravirine + islatravir) for HIV‑1 treatment, and is cited among defensive/counter‑cyclical stock picks — positives for investor sentiment and diversification of approved products. Read More.
• Neutral Sentiment: Progress on M&A: the Hart‑Scott‑Rodino waiting period expired for Merck’s tender offer to acquire Terns Pharmaceuticals, clearing an antitrust procedural hurdle and bringing the acquisition closer to closing — strategic but not immediately earnings‑material. Read More.
• Negative Sentiment: Vaccines headwinds: reports highlight a sharp slump in Gardasil sales in China and Japan, which pressures MRK’s vaccines revenue into the upcoming Q1 results and raises downside risk to top‑line guidance if the trend persists. Read More. Read More.
• Negative Sentiment: Analyst expectations: several analyst notes expect a decline in Q1 earnings and flag that Merck may lack the near‑term drivers for an earnings beat — this raises the risk of downside surprise and explains short‑term selling pressure. Read More. Read More.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MRK. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. TD Cowen upped their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Finally, Guggenheim upped their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $128.47.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.